# US 2003/0215446 A1 · Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215446 A1
- Document ID: US20030215446A1
- Status: Published application
- Kind: A1
- Application number: 10/323,656
- Filed: 2002-12-20
- Published: 2003-11-20
- Earliest claimed: 2001-12-21
- Assignees: Cytokine PharmaSciences, Inc.
- Inventors: John A. Baugh; Richard Bucala; Smita Chitnis; Seamus C. Donnelly; Peter K. Gregersen; Joanita Monteiro
- Web page: https://patentgrep.com/patent/US20030215446A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 38/1709: {from mammals}
- A61K 38/2066: {IL-10}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/245: {IL-1}
- C07K 16/249: {Interferons}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.

## Claims

### Claim 1

A method of diagnosis of severity of a non-infectious inflammatory disease or of a predisposition to severity of a non-infectious inflammatory disease, said method comprising detecting a polymorphism in a human Mif promoter that correlates with an increase or decrease in MIF polypeptide expression, wherein detection of said polymorphism is indicative of the severity of said disease or predisposition to severity of said disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein said non-infectious inflammatory disease is selected from the group consisting of autoimmunity, rheumatoid arthritis and graft versus host disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein said polymorphism in a human Mif promoter is a CATT-tretranucleotide repeat polymorphism at position −817 of the human Mif gene.

### Claim 4 (depends on 3)

The method of claim 3, wherein said CATT-tretranucleotide repeat polymorphism at position −817 of the human Mif gene is selected from the group consisting of 5, 6, 7 and 8 repeat units, and presence of a 5 repeat unit in at least one allele indicates occurrence of or predisposition to low disease severity.

### Claim 5 (depends on 1)

The method of claim 1, comprising amplifying said Mif promoter using a PCR technique.

### Claim 6

A PCR primer set selected to amplify a region of a human Mif promoter, wherein said PCR primer set is selected from the group consisting of: (i) MIF-F (−1024) and MIF-R (−421); (ii) MIF-F (−441) and MIF-R (+4); (iii) MIF-F (−13) and MIF-R (+395); and (iv) MIF-F (+379) and MIF-R (+1043).

### Claim 7 (depends on 6)

A method of detecting a polymorphism in a human Mif promoter region comprising using a primer set of claim 6.

### Claim 8 (depends on 6)

An article of manufacture comprising a PCR primer set of claim 6.

### Claim 9

An isolated nucleic acid molecule comprising a human Mif promoter.

### Claim 10 (depends on 9)

An isolated nucleic acid molecule of claim 9, that is a genomic DNA fragment.

### Claim 11 (depends on 10)

An isolated nucleic acid molecule of claim 10, wherein said genomic DNA fragment has been amplified from a DNA sample of a human subject.

### Claim 12 (depends on 9)

An isolated nucleic acid molecule of claim 9, comprising a portion of a human Mif promoter that comprises a CATT-tretranucleotide repeat polymorphism at position −817 of the human Mif gene.

### Claim 13

A method of inflammatory disease therapy comprising screening an individual for severity of a non-infectious inflammatory disease or of a predisposition to severity of a non-infectious inflammatory disease comprising:
detecting in a human subject a polymorphism in a human Mif promoter that correlates with an increase or decrease in MIF polypeptide expression, wherein detection of said polymorphism is indicative of the severity of said disease or predisposition to severity of said disease; and
treating said human subject to prevent or reduce the severity of said inflammatory disease or to delay the onset of said inflammatory disease.

### Claim 14 (depends on 13)

The method of claim 13, comprising treating said human subject by administering an effective amount of at least one agent selected from the group consisting of an MIF inhibitor, an anti-TNFα antibody, an anti-IL1 antibody, and anti-IFN-γ antibody, IL-1RA, a steroid, a glucocorticoid, and IL-10.

### Claim 15 (depends on 14)

The method of claim 14, wherein said inflammatory disease is rheumatoid arthritis and said polymorphism in a human Mif promoter is a CATT-tretranucleotide repeat polymorphism at position −817 of the human Mif gene.
